BioSpace News Archive

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today shared news of the publication of two independent, retrospective studies evaluating the use of Axumin® (fluciclovine F 18) PET imaging in men with biochemical recurrence of prostate cancer who were undergoing androgen deprivation therapy (ADT).

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2022 conference call on Wednesday, July 27, at 7:30 a.m. CT (8:30 a.m. ET).

NorthStar Medical Radioisotopes today announced the signing of a long-term supply agreement with Clovis Oncology, Inc. (NASDAQ: CLVS) for the therapeutic medical radioisotope, actinium-225 (Ac-225).

Transcat, Inc. announced that it will release its first quarter fiscal year 2023 results after the close of financial markets on Monday, August 1, 2022.

Peptilogics, a biotech company engineering peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s lead drug candidate, PLG0206.

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is announcing the appointment of James Ahlers as Chief Financial Officer (CFO), effective July 15, 2022, and the addition of Ronald B. Kocak as Vice President and Controller for RenovoRx.

PharmaCyte Biotech, Inc. announced today that it has achieved positive interim results in its study to establish a malignant ascites mouse model which will form the basis for further testing of the effectiveness of its CypsCaps™.

Emergent Health Corp. announces it has executed a Letter of Intent to acquire Evolutionary Biologics, Inc.

KromaTiD, a single-cell analysis company focused on the research, development, and commercialization of technology solutions for the cell and gene therapy market, announces the launch of their dGH™ Cell Prep Kit for use in their dGH in-Site™ and dGH SCREEN™ assays.

AURA Devices, the developers of wearable devices to monitor health, wellness, and activity, has scientifically proven its new product, AURA Strap 2.